Medical Advisory Board


Terence J. Colgan, MD – Mount Sinai Hospital
Toronto, Ontario, Canada

Dr. Colgan is an anatomical pathologist, and a practicing cyto- and surgical pathologist, with a particular interest in preventive oncology. Currently, he is head of the gynecological and cytopathology sections of Mount Sinai Hospital and a professor in the Laboratory Medicine & Pathobiology and Obstetrics & Gynecology departments at the University of Toronto. He is actively involved in both teaching and research in pathology, and is an editor for Cancer (Cytopathology), Archives of Pathology and Laboratory Medicine and International Journal of Gynecological Pathology. He is a former chair of the Canadian Society of Cytology, Society of Canadian Colposcopists and was an executive board member of the American Society of Cytopathology.

Robb W. Glenny, MD – University of Washington
Seattle, Washington

Dr. Glenny is the division head of pulmonary and critical care medicine and professor of Medicine, Physiology and Biophysics at the University of Washington. Among his ongoing research interests are translational research in acute lung injury and 3D imaging and computer modeling of the respiratory tract. He has published extensively with more than 120 papers in prestigious journals over the last 20 years. Dr. Glenny is an active member of the American Thoracic Society, American Lung Association and the American Physiologic Society. He is an associate editor for the Journal of Applied Physiology. He received his bachelor’s and master’s degrees from Duke University in biomedical engineering and computer science and his medical doctorate from the University of Virginia.

Edward P. Ingenito, MD, PhD – Harvard Medical School
Boston Massachusetts

Dr. Ingenito is an assistant professor of medicine at the Harvard Medical School. He has specialized in critical care medicine and pulmonary medicine at the Brigham and Women’s Hospital in Boston where he also served as director of the Medical Intensive Care Unit and the Pulmonary Function Lab. Dr. Ingenito has received several awards for outstanding teaching and scholarly work. He has published widely on the subjects of pulmonary function and chronic obstructive pulmonary disease (COPD), and is regarded as a leader in the field. Dr. Ingenito has several patents pending in the area of lung volume reduction therapy for patients who suffer from emphysema. He received his bachelor’s degree in biology, his master’s in mechanical engineering and his PhD in biomedical engineering from MIT and his medical doctorate from the Harvard Medical School.

Harvey Pass, MD – New York University
New York City, New York

Dr. Pass is chief of thoracic surgery specializing in detecting, diagnosing and treating pleural mesothelioma and lung cancer at NYU. He is also a renowned cancer researcher widely known for identifying a mesothelioma biomarker called osteopontin, which helped develop a blood test to detect mesothelioma. Additionally, he is vice chairman of Research for NYU’s Department of Cardiothoracic Surgery and a professor of Thoracic Oncology. Dr. Pass is the current chairman of the Publications Committee for the International Association for the Study of Lung Cancer (IASLC) and board director for the Addario Lung Cancer Medical Institute. He also co-founded the Mesothelioma Applied Research Foundation, dedicated to funding research for a cure and providing support to mesothelioma patients.

Gene F. Pawlick, MD – Former Kaiser Permanente Medical Group
San Mateo, California

Dr. Pawlick was recently medical director at Kaiser Permanente Medical Group, Regional Reference Laboratories in Berkeley and Richmond, California. These laboratories comprise the largest reference clinical laboratory organization in the Kaiser Permanente system, performing more than 70 percent of all laboratory testing. At Kaiser Permanente, Dr. Pawlick pioneered clinical studies in the area of cancer screening and diagnosis and has participated in related hearings at the FDA as a field expert. He is Board Certified in Anatomic and Clinical Pathology.

James Mulshine, MD, Vice Provost – Rush Hospital
Chicago, Illinois

Dr. Mulshine is the associate provost for research and vice president director of Rush Translational Sciences Consortium. His research involves translating basic science into meaningful tools for cancer management, especially for lung cancer management. He has been awarded a number of national and international patents. His research productivity has been recognized with awards from the Department of Commerce, the Public Health Service, the NIH, and the NCI. He is on numerous editorial and foundation boards involved with lung cancer and prevention research. Dr. Mulshine is also a visiting professor at the University of Tokyo Medical University Clinical Proteome Center.

Javier J. Zulueta, MD, FCCP – University of Navarra School of Medicine
Pamplona, Spain

Dr. Zulueta is an associate professor in the department of medicine at the University of Navarra School of Medicine in Pamplona, Spain, where he is director of the pulmonary service. His research interests include lung cancer screening and the use of molecular biomarkers in early lung cancer detection, acute lung injury and cardio-pulmonary exercise physiology, and he has published more than 40 research articles and book chapters. He is a fellow of the American College of Chest Physicians and members of the American Thoracic Society and European Respiratory Society. Dr. Zulueta received his medical doctorate from the Universidad Complutense in Madrid, Spain. His specialization in pulmonary and critical care medicine was at New England Medical Center at Tufts University School of Medicine.

David C. Wilbur, MD, FACP – Massachusetts General Hospital & Harvard Medical School
Boston, Massachusetts

Dr. Wilbur is an anatomic pathologist practicing at Massachusetts General Hospital in Boston, Massachusetts and is professor of pathology at Harvard Medical School. He is currently the director of clinical imaging, and was previously the director of the cytopathology unit.  He has an active practice in the areas of cytopathology, and gynecologic and breast surgical pathology. He is the co-editor of the 3rd edition of the texbook Comprehensive Cytopathology and his relevant research interests include computerization in pathology, most notably automated screening instrumentation and  digital telepathology. Dr. Wilbur received his bachelor’s in biology from Johns Hopkins University and his medical degree from the University of Rochester School of Medicine and Dentistry.

Ralph Aye, MD – Swedish Medical Center
Seattle, Washington

Dr. Ralph Aye is an esophageal and thoracic surgeon at Swedish Medical Center in Seattle, Washington. His current appointments include clinical program leader of thoracic oncology at the Swedish Medical Center, co-director of the Minimally Invasive Thoracic Surgery Program, fellowship director for the Advanced Minimally Invasive Thoracic/Foregut Surgery and teaching attending for the General Surgery Residency Program – all at the Swedish Medical Center. His clinical interests include esophageal achalasia, gastro-esophageal reflux, lung cancer, mediastinal masses, myasthenia gravis, thymoma and tracheal problems. Dr. Aye graduated from the University of Pittsburgh with his residency at New York University and the Swedish Medical Center. He completed a thoracic fellowship in the British health system at Frenchay Hospital in England, and a thoracoesophageal fellowship with Dr. Lucius Hill in Seattle.

Harubumi Kato, MD, Ph.D., Vice President – Tokyo University Medical Center
Tokyo, Japan

Dr. Kato is an emeritus professor at Tokyo Medical College, honorary president of Niizashiki Central General Hospital and a professor at the International University of Health and Wealthfare. He was formerly at Tokyo Medical University as a professor and chairman of its department of surgery. His research interests include systemic medicine including genetics and proteomics. He has a long list of Japanese and international distinctions including visiting researcher at the Karolinska Institute, Sweden, president of the Japan Society for Bronchology, International Academy of Cytology, Japan Broncho-esophagological Society, Japanese Association for Chest Surgery and International Association for the Study of Lung Cancer, and chairman of the Japan Society for Laser Surgery and Medicine, Clinical Proteome Center at Tokyo Medical University, Japanese Society of Clinical Cytology and the Japan Lung Cancer Society. Dr. Kato received his medical doctorate and PhD from Tokyo Medical University.


This website may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and made in reliance on the "safe harbor" provisions of said act. Forward-looking statements are based on estimates, projections, beliefs and assumptions of VisionGate® management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. Forward-looking statements are subject to change without notice.

Contact Us

If you are interested in learning more about VisionGate and would like to speak with someone, please complete this short inquiry form and a representative will contact you as soon as possible.


Copyright 2017 - VisionGate, Inc.